

India: India Responsive COVID-19 Vaccines for Recovery

1. Project Information

Project ID:	P000564	Instrument ID:	L0564A
Member:	India	Region:	Southern Asia
Sector:	CRF-Public Health	Sub-sector:	N/A
Instrument type:	<input checked="" type="checkbox"/> Loan:500.00 US Dollar million <input type="checkbox"/> Guarantee	Co-financier(s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Ministry of Finance, India
Implementing Entity:	Ministry of Health and Family Welfare, India		
Project Team Leader:	Ankur Agrawal		
Responsible DG:	Rajat Misra		
Responsible Department:	INF1		
Project Team Members:	Rabindra Shah, OSD - Procurement Specialist; Yogesh Malla, OSD - Financial Management Specialist; Calvin Quek, OSD - Environment & Social Development Specialist; Hari Bhaskar, Team Member; Christopher Damandl, Project Counsel; Aditi Khosla, Alternate Counsel; Jinghui Li, Project admin;		
Completed Site Visits by AIIB:			
Planned Site Visits by AIIB:	Sep, 2022 Meeting with the implementing agency will be scheduled in Q3FY22.		
Current Red Flags Assigned:	0		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:			
Previous Red Flags Assigned Date:			

2. Project Summary and Objectives

The objective of the Project is to vaccinate eligible populations against COVID-19 in the selected states of India (project states).

The Project will support the procurement of safe and effective vaccines against COVID-19. The project has been co-financed with the Asian Development Bank (ADB) under the rapid response component of ADB's Asia Pacific Vaccine Access Facility (APVAX).

The total Project cost is USD 2.058 billion which has been financed by AIIB to the extent of USD500 million (24.30 percent), by ADB to the extent of USD1.5 billion (72.89 percent) and the remaining USD 57.77 million (2.81 percent) by the Government of India (GoI). The loan proceeds from AIIB and ADB will finance expenditures relating to the procurement of COVID-19 vaccines that meet the APVAX eligibility criteria. The GoI fund will cover financial charges during implementation, including interest, commitment charges and front-end fee. The GoI will also provide in-kind contributions in the form of counterpart staff, logistics, cold

chain infrastructure, and other facilities.

The Project is expected to procure at least 667 million doses of vaccines, which will be administered to a target population by 2024 in accordance with the current NDVP for COVID-19 vaccines and any subsequent guidelines. The Project is to cover at least 317 million beneficiaries.

3. Key Dates

Approval:	Jan. 20, 2022	Signing:	Jan. 21, 2022
Effective:	Feb. 10, 2022	Restructured (if any):	
Orig. Closing:	Jun. 30, 2025	Rev. Closing (if any):	

4. Disbursement Summary (USD million)

Contract Awarded:		Cancellation (if any):	0.00
Disbursed:	250.00	Most recent disbursement (amount/date):	75.96/Jun. 24, 2022
Undisbursed:	250.00	Disbursement Ratio (%) ¹ :	50.00

5. Project Implementation Update

AIIB has disbursed the entire portion of retroactive financing of USD250 million. Additionally, AIIB has disbursed USD75.9 on June 24, 2022. The entire financing has been towards the procurement of vaccines from two manufacturers - Serum Institute of India and Bharat Biotech International Limited.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	AIIB has disbursed the entire portion of retroactive financing of USD250 million. Additionally, AIIB has disbursed USD75.9 on June 24, 2022. The entire financing has been towards the procurement of vaccines from two manufacturers - Serum Institute of India and Bharat Biotech International Limited.	Under ADB's Safeguard Policy Statement (SPS), the project has been categorized as C for Environment, Involuntary Resettlement, and Indigenous Peoples on the basis that no adverse ES impacts are expected.	AIIB has disbursed the entire portion of retroactive financing of USD250 million. Additionally, AIIB has disbursed USD75.9 on June 24, 2022. The entire financing has been towards the procurement of vaccines from two manufacturers - Serum Institute of India and Bharat Biotech International Limited.

Financial Management:

Total disbursement is about USD325.9 million and of which USD239.46 million was disbursed in FY21-22 (April 2021-March 2022). The project has a dedicated budget line item and the internal audit team has been finalized for FY21-22. The audited project financial statements for FY21-22 is due on September 30, 2022.

¹ Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

6. Status of the Grievance Redress Mechanism (GRM)

MOHFW has been operating a toll free 24x7 national helpline '1075' and another helpline (011-23978046) for addressing queries related to the COVID- 19 pandemic, vaccine rollout and the Co-WIN software. In addition to 1075, a technical helpline (0120-4473222) has been established to specifically handle Co-WIN software-related queries. Any technical issue which is not resolved by 1075 is directed to the Technical Helpline for resolution. MOHFW has also created an email id (ncov2019@gov.in) for addressing COVID-19 related queries and grievances in addition to providing a repository of state COVID-19 helplines and website links for relevant resources, on its website - <https://www.mohfw.gov.in/>. State 104 helplines have been augmented to address queries on COVID-19 vaccination including grievance redressal related to vaccination process as well as linking to concerned facilities for management of any adverse event. As per guidelines, all grievances are to be reviewed at regular intervals at the level of state task force, district task force, urban task force, and block task force.

7. Results Monitoring

Results shall be monitored in due course.

Project Objective Indicators #1

At least 317 million targeted people (at least 47.5% women) vaccinated with at least two doses against COVID-19 in project states.

Year	Target	Actual	Comments, if any
Aug. 16, 2021	-	-	Baseline: male: 52.6%, female:46.8%, others: 0.6%
Dec. 31, 2022	-	-	
Dec. 31, 2023	-	-	
Dec. 31, 2024	317 million, 47.5% of them women	-	

Project Objective Indicators #2

By 2024, at least 667 million doses of COVID-19 vaccine procured and delivered to the project states.

Year	Target	Actual	Comments, if any
Aug. 16, 2021	-	-	Baseline: 0
Dec. 31, 2022	-	-	
Dec. 31, 2023	-	-	
Dec. 31, 2024	667 million doses	-	

Remarks: